Prognostic Factors for 10-Year Survival in Patients With Hepatocellular Cancer Receiving Liver Transplantation.
Milan criteria
alpha-fetoprotein
expanded criteria
radiological response
recurrence
Journal
Frontiers in oncology
ISSN: 2234-943X
Titre abrégé: Front Oncol
Pays: Switzerland
ID NLM: 101568867
Informations de publication
Date de publication:
2022
2022
Historique:
received:
16
02
2022
accepted:
29
03
2022
entrez:
16
5
2022
pubmed:
17
5
2022
medline:
17
5
2022
Statut:
epublish
Résumé
Long-term survival after liver transplantation (LT) for hepatocellular cancer (HCC) continues to increase along with the modification of inclusion criteria. This study aimed at identifying risk factors for 5- and 10-year overall and HCC-specific death after LT. A total of 1,854 HCC transplant recipients from 10 European centers during the period 1987-2015 were analyzed. The population was divided in three eras, defined by landmark changes in HCC transplantability indications. Multivariable logistic regression analyses were used to evaluate the significance of independent risk factors for survival. Five- and 10-year overall survival (OS) rates were 68.1% and 54.4%, respectively. Two-hundred forty-two patients (13.1%) had HCC recurrence. Five- and 10-year recurrence rates were 16.2% and 20.3%. HCC-related deaths peaked at 2 years after LT (51.1% of all HCC-related deaths) and decreased to a high 30.8% in the interval of 6 to 10 years after LT. The risk factors for 10-year OS were macrovascular invasion (OR = 2.71; P = 0.001), poor grading (OR = 1.56; P = 0.001), HCV status (OR = 1.39; P = 0.001), diameter of the target lesion (OR = 1.09; P = 0.001), AFP slope (OR = 1.63; P = 0.006), and patient age (OR = 0.99; P = 0.01). The risk factor for 10-year HCC-related death were AFP slope (OR = 4.95; P < 0.0001), microvascular (OR = 2.13; P < 0.0001) and macrovascular invasion (OR = 2.32; P = 0.01), poor tumor grading (OR = 1.95; P = 0.001), total number of neo-adjuvant therapies (OR = 1.11; P = 0.001), diameter of the target lesion (OR = 1.11; P = 0.002), and patient age (OR = 0.97; P = 0.001). When analyzing survival rates in function of LT era, a progressive improvement of the results was observed, with patients transplanted during the period 2007-2015 showing 5- and 10-year death rates of 26.8% and 38.9% (vs. 1987-1996, P < 0.0001; vs. 1997-2006, P = 0.005). LT generates long-term overall and disease-free survival rates superior to all other oncologic treatments of HCC. The role of LT in the modern treatment of HCC becomes even more valued when the follow-up period reaches at least 10 years. The results of LT continue to improve even when prudently widening the inclusion criteria for transplantation. Despite the incidence of HCC recurrence is highest during the first 5 years post-transplant, one-third of them occur later, indicating the importance of a life-long follow-up of these patients.
Sections du résumé
Background
UNASSIGNED
Long-term survival after liver transplantation (LT) for hepatocellular cancer (HCC) continues to increase along with the modification of inclusion criteria. This study aimed at identifying risk factors for 5- and 10-year overall and HCC-specific death after LT.
Methods
UNASSIGNED
A total of 1,854 HCC transplant recipients from 10 European centers during the period 1987-2015 were analyzed. The population was divided in three eras, defined by landmark changes in HCC transplantability indications. Multivariable logistic regression analyses were used to evaluate the significance of independent risk factors for survival.
Results
UNASSIGNED
Five- and 10-year overall survival (OS) rates were 68.1% and 54.4%, respectively. Two-hundred forty-two patients (13.1%) had HCC recurrence. Five- and 10-year recurrence rates were 16.2% and 20.3%. HCC-related deaths peaked at 2 years after LT (51.1% of all HCC-related deaths) and decreased to a high 30.8% in the interval of 6 to 10 years after LT. The risk factors for 10-year OS were macrovascular invasion (OR = 2.71; P = 0.001), poor grading (OR = 1.56; P = 0.001), HCV status (OR = 1.39; P = 0.001), diameter of the target lesion (OR = 1.09; P = 0.001), AFP slope (OR = 1.63; P = 0.006), and patient age (OR = 0.99; P = 0.01). The risk factor for 10-year HCC-related death were AFP slope (OR = 4.95; P < 0.0001), microvascular (OR = 2.13; P < 0.0001) and macrovascular invasion (OR = 2.32; P = 0.01), poor tumor grading (OR = 1.95; P = 0.001), total number of neo-adjuvant therapies (OR = 1.11; P = 0.001), diameter of the target lesion (OR = 1.11; P = 0.002), and patient age (OR = 0.97; P = 0.001). When analyzing survival rates in function of LT era, a progressive improvement of the results was observed, with patients transplanted during the period 2007-2015 showing 5- and 10-year death rates of 26.8% and 38.9% (vs. 1987-1996, P < 0.0001; vs. 1997-2006, P = 0.005).
Conclusions
UNASSIGNED
LT generates long-term overall and disease-free survival rates superior to all other oncologic treatments of HCC. The role of LT in the modern treatment of HCC becomes even more valued when the follow-up period reaches at least 10 years. The results of LT continue to improve even when prudently widening the inclusion criteria for transplantation. Despite the incidence of HCC recurrence is highest during the first 5 years post-transplant, one-third of them occur later, indicating the importance of a life-long follow-up of these patients.
Identifiants
pubmed: 35574299
doi: 10.3389/fonc.2022.877107
pmc: PMC9093683
doi:
Types de publication
Journal Article
Langues
eng
Pagination
877107Informations de copyright
Copyright © 2022 Lai, Viveiros, Iesari, Vitale, Mennini, Onali, Hoppe-Lotichius, Colasanti, Manzia, Mocchegiani, Spoletini, Agnes, Vivarelli, Tisone, Ettorre, Mittler, Tsochatzis, Rossi, Cillo, Schaefer and Lerut.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Hepatology. 2020 Dec;72(6):2014-2028
pubmed: 32124453
Biomed Res Int. 2021 Mar 19;2021:6638117
pubmed: 34150908
Transl Gastroenterol Hepatol. 2017 Oct 12;2:80
pubmed: 29167827
Lancet. 2007 Oct 20;370(9596):1453-7
pubmed: 18064739
Am J Transplant. 2018 May;18(5):1206-1213
pubmed: 29068145
Transplantation. 2003 Sep 15;76(5):871-3
pubmed: 14501871
Transpl Int. 2020 May;33(5):567-575
pubmed: 31994238
N Engl J Med. 1996 Mar 14;334(11):693-9
pubmed: 8594428
Ann Surg. 2016 Nov;264(5):787-796
pubmed: 27429025
J Korean Med Sci. 2014 Oct;29(10):1360-6
pubmed: 25368488
Lancet Oncol. 2009 Jan;10(1):35-43
pubmed: 19058754
Liver Transpl. 2017 Jun;23(6):836-844
pubmed: 28295992
Dig Liver Dis. 2022 Apr;54(4):452-460
pubmed: 35131176
Liver Transpl. 2021 Dec;27(12):1758-1766
pubmed: 34355489
Transplantation. 2020 Jun;104(6):1136-1142
pubmed: 32217938
J Hepatol. 2014 Jun;60(6):1165-71
pubmed: 24508550
Liver Transpl. 2019 Jul;25(7):1023-1033
pubmed: 31087772
Cancer Lett. 2015 Feb 1;357(1):47-54
pubmed: 25444925
Updates Surg. 2021 Oct;73(5):1599-1614
pubmed: 34003479
Hepatobiliary Pancreat Dis Int. 2019 Dec;18(6):517-524
pubmed: 31151807
Cancers (Basel). 2019 Oct 30;11(11):
pubmed: 31671581
Hepatology. 2001 Jun;33(6):1394-403
pubmed: 11391528
Transplantation. 2020 Oct;104(10):2105-2112
pubmed: 31972705
Hepatogastroenterology. 1990 Apr;37(2):188-93
pubmed: 2160421
Dig Liver Dis. 2018 Nov;50(11):1105-1114
pubmed: 30170908
Gut. 2023 Jan;72(1):141-152
pubmed: 34933916
Transpl Int. 2018 Dec;31(12):1293-1317
pubmed: 30259574
Korean J Anesthesiol. 2013 May;64(5):402-6
pubmed: 23741561
Liver Transpl. 2011 Oct;17 Suppl 2:S44-57
pubmed: 21695773
HPB (Oxford). 2018 Aug;20(8):768-775
pubmed: 29622402
Am J Transplant. 2010 Jan;10(1):129-37
pubmed: 20070666
Ann Surg. 1991 Sep;214(3):221-8; discussion 228-9
pubmed: 1656903
Ann Surg. 2000 Oct;232(4):490-500
pubmed: 10998647
Transplantation. 2018 May;102(5):816-822
pubmed: 29505494